openPR Logo
Press release

Influenza Pipeline Insight 2022 by DelveInsight

08-05-2022 06:08 AM CET | Health & Medicine

Press release from: DelveInsight Business Research

Influenza Pipeline

Influenza Pipeline

DelveInsight's, Influenza Pipeline Insight 2022 report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in Influenza pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To know more about Influenza Pipeline Report: https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Influenza Overview
Influenza, one of the most common infectious diseases, is a highly contagious airborne disease that occurs in seasonal epidemics and manifests as an acute febrile illness with variable degrees of systemic symptoms, ranging from mild fatigue to respiratory failure and death. Influenza causes significant loss of workdays, human suffering, and mortality. The CDC documented that seasonal influenza was responsible for 24,000 to 62,000 deaths during the 2019-2020 season. Information used to generate influenza in-season burden estimates were too low during the 2020-2021 season to provide an estimate.

Download Sample Report- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Influenza Pathophysiology
Influenza is an acute disease that targets the upper respiratory tract and causes inflammation of the upper respiratory tree and trachea. The acute symptoms persist for seven to ten days, and the disease is self-limited in most healthy individuals. The immune reaction to the viral infection and the interferon response are responsible for the viral syndrome that includes high fever, coryza, and body aches. High-risk groups who have chronic lung diseases, cardiac disease, and pregnancy are more prone to severe complications such as primary viral pneumonia, secondary bacterial pneumonia, hemorrhagic bronchitis, and death. These severe complications can develop in as little as 48 hours from the beginning of symptoms. The virus replicates in the upper and lower respiratory passages starting from the time of inoculation and peaking after 48 hours, on average.

Influenza Emerging Drugs
• mRNA-1010: Moderna
• SAB-176: SAB Biotherapeutics
• INNA-051: ENA Respiratory Pty Ltd
• CODA-VAX H1N1: Codagenix
• ALVR106: AlloVir

To know more about Influenza Pipeline therapies, click here: https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Influenza Pipeline Therapeutic Assessment
• Influenza Assessment by Product Type
• Influenza By Stage and Product Type
• Influenza Assessment by Route of Administration
• Influenza By Stage and Route of Administration
• Influenza Assessment by Molecule Type
• Influenza by Stage and Molecule Type

Influenza Treatment
Antiviral medications can be used to treat or prevent influenza infection, especially during outbreaks in healthcare settings such as hospitals and residential institutions. Oseltamivir, zanamivir, and peramivir belong to the neuraminidase inhibitors family and can be used for the treatment of influenza A and B. The adamantanes antiviral family has two medications, amantadine, and rimantadine.

Learn more about influenza therapies- https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Influenza Pipeline Companies
• Moderna
• SAB Biotherapeutics
• ENA Respiratory Pty Ltd
• Codagenix
• AlloVir
• Osivax
• CureVac AG
• GlaxoSmithKline
• Cocrystal Pharma Inc
• Viriom
• Emergent BioSolutions
• Pfizer
• Jiangxi Qingfeng Pharmaceutical Co. Ltd.
• Guangdong Raynovent Biotech Co., Ltd
• FluGen Inc
• BlueWillow Biologics
• AVM Biotechnology LLC
• Ansun Biopharma, Inc.
• Guangzhou Henovcom Bioscience
• Sunshine Lake Pharma Co., Ltd.
• Emergex Vaccines
• Vir Biotechnology
• CSL Limited
• Novavax
• EMERGENT
• Mitsubishi Chemical Group Corporation
• Poolbeg Pharma
• MYMETICS
• CELLTRION INC.
• Avalia Immunotherapies
• Meiji Holdings Co., Ltd.
• Clover Biopharmaceuticals
• Airway Therapeutics, Inc.
• PrEP Biopharm
• Ansun Biopharma
• Cidara Therapeutics, Inc., and several others

To know more about Influenza Companies, click here: https://www.delveinsight.com/report-store/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Influenza Pipeline Phases
DelveInsight's report covers around 120+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Influenza Pipeline Report Highlights
• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Influenza.
• In the coming years, the Influenza market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Influenza R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Influenza treatment market. Several potential therapies for Influenza are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Influenza market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Influenza) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Table of Content
• Introduction
• Executive Summary
• Influenza: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Influenza - DelveInsight's Analytical Perspective
• Late Stage Products (Phase III)
• mRNA-1010: Moderna
• Mid Stage Products (Phase II)
• INNA-051: ENA Respiratory Pty Ltd
• Early Stage Products (Phase I)
• CODA-VAX H1N1: Codagenix
• Preclinical and Discovery Stage Products
• Drug name: Company name
• Inactive Products
• Influenza Key Companies
• Influenza Key Products
• Influenza- Unmet Needs
• Influenza- Market Drivers and Barriers
• Influenza- Future Perspectives and Conclusion
• Influenza Analyst Views
• Influenza Key Companies
• Appendix

Request for Influenza sample pages, click here: https://www.delveinsight.com/sample-request/influenza-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Influenza Pipeline Insight 2022 by DelveInsight here

News-ID: 2698549 • Views: 1921

More Releases from DelveInsight Business Research

Acne Vulgaris Pipeline Assessment | Insights into the Marketed and Emerging Ther …
The main goal of acne treatment is to control and treat existing acne lesions, prevent permanent scarring as far as possible, limit the duration of the disorder and to minimize morbidity. Treatment options includes topical therapies (retinoids, and antibiotics), systemic therapies (retinoids, antibiotics, and hormonal), and complementary and alternative medicines (CAM). The physical therapies such as comedone extraction, cryoslush therapy, cryotherapy, electrocauterization, intralesional corticosteroids and optical treatments are also used. "Acne
Allergic Rhinitis Pipeline Assessment | Insights into the Marketed and Emerging …
The treatment goal for allergic rhinitis is relief of symptoms. Therapeutic options available to achieve this goal include avoidance measures, nasal saline irrigation, oral antihistamines, intranasal corticosteroids, combination intranasal corticosteroid/antihistamine sprays; leukotriene receptor antagonists (LTRAs), and allergen immunotherapy. Other therapies that may be useful in select patients include decongestants and oral corticosteroids. "Allergic Rhinitis Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects
Alzheimer's disease Market to Witness Upsurge in Growth During the Forecast Peri …
The Alzheimer's disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Alzheimer's disease market dynamics. DelveInsight's "Alzheimer's disease Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of Alzheimer's disease, historical and forecasted epidemiology as well as the Alzheimer's disease market trends in the United States, EU5 (Germany, Spain,
Globally, More than 100+ Key Companies are working in the Multiple Myeloma Pipel …
DelveInsight's Multiple Myeloma Pipeline Insights 2022," report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. The Multiple Myeloma Pipeline report also provides the inactive products

All 5 Releases


More Releases for Influenza

Influenza Vaccine Market | DPIResearch.com
According to the DPI Research new growth forecast report titled “Worldwide Influenza Vaccines Market Size | Forecast to 2027” to Witness Comprehensive Growth by 2027 DPI Research published a new report on Worldwide Influenza Vaccines Market. The research offers an extensive analysis of key players active in the Worldwide Influenza Vaccines Market. Detailed analysis on operating business segments, product portfolio, business performance, and key strategic developments is offered in the research.
Global Influenza Vaccines Market
Global Influenza Vaccines Market Size, Share, Analysis, Growth, Trends, and Forecast to 2027 Worldwide Influenza Vaccines Market size is expected to exceed USD 7.5 billion by 2027. The report contains a deep analysis of the worldwide influenza vaccines market with size in terms of both value and volume. The report provides a clear insight into current and future developments of the worldwide influenza vaccines market. The report also explores a detailed analysis
Influenza Diagnostics Market – Screening Product Awareness 2025
Global Influenza Diagnostics Market: Snapshot The global market for influenza diagnostics is slated to expand at a promising pace in the next few years as the incidences of influence are rising at a massive pace on the globe front. A common illness of the respiratory system, the condition is responsible for between 250,000 to 500,000 deaths across the globe every year. As the virulent spread of the condition creates increased concerns
Influenza Diagnostics Market
Influenza, commonly known as flu, is an infectious disease caused by the influenza virus. Three varieties of this virus affect people: type A, type B, and type C. Influenza spreads through infectious respiratory secretions caused by aerosol formation due to direct contact with an infected person. This virus can cause seasonal epidemics with high levels of morbidity and mortality. According to WHO, these epidemics were estimated to result in about
Global Influenza Vaccine Market Forecast
Global Influenza Vaccine Market is worth more than US$ 5 Billion. Globally Pediatrics Influenza Vaccinated Population was more than 150 Thousand, but still this figure was significantly less than the Adult Influenza Vaccinated Population. As per our research Pediatrics Influenza Vaccinated population will decline in future and Adult Influenza Vaccinated Population will increase in forecast period. United States has the highest market share in Influenza Vaccine Market. United States Influenza Vaccine
Influenza Diagnostics Market Analysis – 2024
Influenza, commonly known as flu, is an infectious disease caused by the influenza virus. Three varieties of this virus affect people: type A, type B, and type C. Influenza spreads through infectious respiratory secretions caused by aerosol formation due to direct contact with an infected person. This virus can cause seasonal epidemics with high levels of morbidity and mortality. According to WHO, these epidemics were estimated to result in about